Faculty Information - HASHIMOTO Yasunobu

（Last updated : 2026-10-02 14:51:42）

HASHIMOTO Yasunobu
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Other	Effectiveness and safety of enfortumab vedotin plus pembrolizumab for patients aged 80 years and older with metastatic urothelial carcinoma: A multicenter retrospective study. 2026/08
2.	Original article	Real‑world outcomes of adjuvant pembrolizumab for renal cell carcinoma: The potential role of PD‑L1 as a prognostic biomarker. 2026/07
3.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
4.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
5.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
6.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
7.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
8.	Original article	Midterm outcomes of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs in real-world patients with advanced renal cell carcinoma. 2026/03
9.	Case report	Anti-melanoma differentiation-associated Gene 5 antibody-positive interstitial lung disease, Induced by enfortumab vedotin plus pembrolizumab for Advanced urothelial carcinoma. 2026/02/05
10.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
11.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
12.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
13.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
14.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
15.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
16.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
17.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
18.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
19.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
20.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
21.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
22.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
23.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
24.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
25.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
26.	Original article	Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma. 2023/10
27.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
28.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
29.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
30.	Original article	Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma. 2023/02
31.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
32.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
33.	Original article	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. 2022/07/08
34.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
35.	Original article	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. 2022/02
36.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
37.	Original article	Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma 2021/12
38.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
39.	Original article	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 2021/10
40.	Original article	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. 2021/10
41.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
42.	Original article	A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer. 2021/03
43.	Original article	Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. 2021/03
44.	Original article	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. 2020/08
45.	Original article	Prognostic value of the LATITUDE and CHAARTED risk criteria for predicting the survival of men with bone metastatic hormone-naïve prostate cancer treated with combined androgen blockade therapy: Real-world data from a Japanese multi-institutional study. 2020/07
46.	Original article	Follow-up Survey of Donor Candidates for Living Related Kidney Transplantation With Prostate Cancer. 2018/10
47.	Original article	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. 2017/02
48.	Original article	Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-Metastatic Renal Cancer in Long-Term Dialysis Patients. 2017/02
49.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
50.	Original article	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. 2017/02
51.	Original article	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. 2016/10
52.	Original article	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. 2016/09
53.	Original article	Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases. 2016/07
54.	Original article	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. 2016/06
55.	Case report	Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients 2016/04/01
56.	Original article	Efficacy and feasibility of low-dose rate brachytherapy for prostate cancer in renal transplant recipients. 2016/04/01
57.	Original article	Robot-assisted radical prostatectomy for localized prostate cancer in asian renal transplant recipients. 2016/04
58.	Original article	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. 2016/02
59.	Original article	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. 2015/12
60.	Other	Possible impact of continuous drainage after minimally invasive partial nephrectomy. 2015/11
61.	Original article	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. 2015/10
62.	Original article	Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for ≥T1b renal tumors. 2015/09
63.	Case report	Combination of molecular targeted therapy and surgery for a patient with metastatic renal cell carcinoma with a poor prognosis. 2015/07
64.	Original article	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. 2015/04
65.	Original article	Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. 2014/12
66.	Original article	Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease. 2014/11
67.	Original article	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. 2014/06
68.	Original article	Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. 2014/05
69.	Case report	Cystic local recurrence of renal cell carcinoma after laparoscopic radical nephrectomy in a hemodialysis patient. 2014/03
70.	Original article	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off 2014/03
71.	Original article	Mannitol has no impact on renal function after open partial nephrectomy in solitary kidneys 2014/02
72.	Original article	The influence of RENAL nephrometry score on pre-ruptured pseudoaneurysm formation detected by computed tomography angiography in early postoperative period after minimally invasive partial nephrectomy. 2014/01
73.	Original article	The utility of monitoring serum KL-6 level for predicting the onset of mTOR inhibitors induced interstitial lung disease 2013/07
74.	Original article	Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to Treatment Era Including Cytokine and Targeted Therapy 2013/04
75.	Original article	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience 2013
76.	Original article	Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma 2012/11
77.	Original article	Cytoreductive nephrectomy for pT3b-T4 M1 renal cell carcinoma in 39 patients: single center analysis 2012/09
78.	Original article	Predictors for postoperative renal function after open partial nephrectomy: Including postoperative biomarkers 2012/09
79.	Original article	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancer-specific survival 2011/12
80.	Original article	Analysis of laparoscopic radical nephrectomy for renal cell carcinoma patients with end stage kidney disease requiring hemodialysis 2011/09
81.	Original article	Postoperative renal function after partial nephrectomy for renal cell carcinoma in patients with pre-existing chronic kidney disease: a comparison with radical nephrectomy 2011/06
82.	Original article	Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center 2011/05
83.	Original article	Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. 2010/12
84.	Original article	Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients 2010/07
85.	Original article	Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. 2010
86.	Original article	Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. 2010
87.	Original article	Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. 2009/03
88.	Original article	Clinical outcome of high-grade non-muscle-invasive bladder cancer: A long-term single center experience 2009
89.	Review article	Authors reply to Minimal impact of cold ischemic time on the development of high stage chronic kidney disease observed long-term after partial nephrectomy 2008/11
90.	Original article	Minimal Effect of Cold Ischemia Time on Progression to Late-Stage Chronic Kidney Disease Observed Long Term After Partial Nephrectomy 2008/11
91.	Original article	Continent Orthotopic Ileal Neobladder After Kidney Transplantation in a Patient With Urothelial Cell Carcinoma Associated With Chinese Herb Nephropathy 2008/06
92.	Original article	Impact of the Extent of Regional Lymphadenectomy on the Survival of Patients With Urothelial Carcinoma of the Upper Urinary Tract 2007/10
93.	Original article	Successful testis preservation for bilateral testicular tumors with a new chemotherapy-based protocol: Initial results of three cases 2007/09
94.	Original article	Primary Site and Incidence of Lymph Node Metastases in Urothelial Carcinoma of Upper Urinary Tract 2007/02
95.	Original article	Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response 2006/08
Display 5 items
Display all(95)

■ Academic conference presentation

1.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （Poster notice，General） 2026/05/18
2.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （Poster notice，General） 2026/05/16
3.	Initial experience with enfortumab vedotin-pembrolizumab at our hospital. （Speech，General） 2026/04/25
4.	Multicenter study of polypharmacy and perioperative outcomes in robot-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion (ICUD). （Poster notice，General） 2026/04/24
5.	Real world data of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma: Multi-center retrospective study in Japan. （Speech，General） 2026/04/24
6.	Efficacy of triplet therapy in metastatic castration-sensitive prostate cancer patients at our hospital. （Speech，General） 2026/04/23
7.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
8.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
9.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （Poster notice，General） 2026/04/23
10.	Early experience of focal therapy using high-intensity focused ultrasound in localized prostate cancer. （Poster notice，General） 2025/10/19
11.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
12.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
13.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
14.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
15.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
16.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
17.	Initial experience with robot-assisted radical cystectomy+ ICUD at our hospital. （Poster notice，General） 2024/04/26
18.	Initial experience with robot-assisted total nephroureterectomy at our hospital. （Poster notice，General） 2024/04/26
19.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
20.	Initial experience with enfoltumab vedotin therapy for urothelial carcinoma at Saiseikai Kawaguchi General Hospital. （Poster notice，General） 2024/04/25
21.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
22.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
23.	Surgical results of laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma at Saiseikai Kawaguchi General Hospital. （Poster notice，General） 2023/04/22
24.	A Clinical review of 20 with hemodialysis patients renal cell carcinomas who underwent nephrectomy at Saiseikai Kawaguchi General Hospital. （Poster notice，General） 2023/04/21
25.	Localization of prostate cancer using MRI-TRUS fusion image-guided transperineal Biojet prostate target biopsy - comparison with prostatectomy specimen - （Poster notice，General） 2023/04/20
26.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
27.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
28.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
29.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
30.	Predictive impact of early changes in serum c-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
31.	Medication adherence and treatment outcome in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. （Speech，General） 2020/12/24
32.	A new predictive model for prognosis in oligometastatic prostate cancer. （Speech，General） 2020/12/23
33.	Predictive factors related to the number of TUL for kidney stones in our hospital. （Poster notice，General） 2020/12/22
34.	Treatment outcome of abiraterone plus prednisone in patients with high-risk metastatic castration-sensitive prostate cancer in Saiseikai Kawaguchi hospital. （Poster notice，General） 2020/12/22
35.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical recurrence in patients with prostate cancer treated with radiotherapy. （Poster notice，General） 2019/05/06
36.	Investigation of introduction of early docetaxel for mHRCP in our hospital. （Poster notice，General） 2018/10/21
37.	Utility of whole body MRI for detection and treatment of metastases of prostate cancer. （Poster notice，General） 2018/10/21
38.	Combined androgen blockade as first-line therapy for men with high-risk metastatic hormone-naïve prostate cancer. （Poster notice，General） 2018/10/20
39.	Robotic surgeries for urological malignancies in renal transplant recipients （Speech，Special/Invited Lecture） 2018/10/05
40.	Effect of luteinizing hormone-eleasing hormone antagonist on testosterone recovery after neoadjuvant therapy with or without adjuvant androgen deprivation and radiotherapy for localized prostate cancer. （Poster notice，General） 2018/05/21
41.	Superior efficacy of degarelix as neoadjuvant hormone therapy in control of acute genitourinary toxicity associated with radiation therapy for prostate cancer compared to LHRH agonist; A propensity-score matching analysis. （Poster notice，General） 2018/05/21
42.	Clinicopathological analysis of prostate cancer in patients with renal transplant recipients. （Poster notice，General） 2018/05/20
43.	Usefulness of the modified Glasgow Prognostic Score (mGPS) in patients with castration- sensitive prostate cancer: muti- institutional study. （Poster notice） 2018/04/19
44.	Redical Prostatectomy for Localized Prostate Cancer in Renal Transplant Recipients:13 Cases Studied at a Single Center （Poster notice，General） 2017/11/28
45.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical recurrence in patients with prostate cancer treated with radiotherapy. （Speech，General） 2017/08/19
46.	Higher risk of recurrence at extraregional nodes after radical nephroureterectomy in patients with left than in patients with right ureteral cancer （Speech，General） 2017/05/15
47.	Usefulness of multiparametric MRI in prognosis for high risk prostate cancer after radiotherapy. （Poster notice，General） 2017/04/21
48.	Comparison of surgical and oncologic outcomes between long-term and short-term dialysis patients undergoing laparoscopic radical nephrectomy for non-metastatic renal cancer. （Poster notice，General） 2016/11/09
49.	Efficacy and feasibility of radiotherapy for localized prostate cancer in renal transplant recipients: a single-center experience. （Poster notice，General） 2016/08/20
50.	Treatment of upper urinary tract stones over 2cm in size with TUL assisted PNL (TAP). （Poster notice，General） 2016/07/19
51.	Risk factors for asymptomatic renal artery pseudoaneurysm after partial nephrectomy detected by enhanced CT in the early postoperative period. （Poster notice，General） 2016/05/09
52.	Assessment of surgical outcomes of the non-renorrhaphy technique in open partial nephrectomy for =T1B renal tumors. （Poster notice，General） 2016/05/08
53.	Preoperative prostate imaging reporting and data system score: An independent predictor of positive surgical margin after robot-assisted radical prostatectomy. （Poster notice，General） 2016/05/08
54.	Prostate imaging reporting and data system score before prostate biopsy can predict biochemical failure in prostate cancer patients treated with high-dose-rate brachytherapy. （Poster notice，General） 2016/05/06
55.	Lymphatic metastases from the urothelial carcinoma of the left lower ureter spreads more extensively at higher incidence than the tumors of the right side. （Speech） 2016/04/24
56.	Risk factors for asymptomatic renal artery pseudoaneurysm after partial nephrectomy detected by enhanced CT in the early postoperative period. （Poster notice，General） 2016/03/14
57.	Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience. （Speech，Panelist at Symposium/Workshop (Other)） 2015/10/30
58.	Early unclamping technique significantly increases the probability of achieving pentafecta after robot-assisted laparoscopic partial nephrectomy. （Poster notice，General） 2015/10/03
59.	endGIA decreased Positive Margin of Apex in Laparoscopic Radical Prostatectomy. （Poster notice，General） 2015/10/02
60.	Ho:YAG laser ablation for ulcerative interstitial cystitis. （Poster notice，General） 2015/10
61.	Efficacy and feasibility of intensity-modulated radiation therapy for prostate cancer in renal-transplant recipients. （Poster notice，General） 2015/08/26
62.	Efficacy and feasibility of low-dose brachytherapy for prostate cancer in renal-transplant recipients. （Poster notice，General） 2015/08/26
63.	Robot-assisted radical prostatectomy in renal transplant recipients: the first report in asian patient. （Poster notice，General） 2015/08/26
64.	The relationship between the timing of maximum tumor shrinkage during 1st-line targeted therapy and overall survival of patients with metastatic renal cell carcinoma. （Poster notice，General） 2015/05/18
65.	Comparison of survival rates in stage one renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution. （Poster notice，General） 2015/05/17
66.	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence in patients with upper/middle ureteral cancer. （Poster notice，General） 2015/05/15
67.	Botulinum toxin A treatment outcome in overactive bladder. （Poster notice，General） 2015/02/11
68.	Botulinum Toxin A Treatment outcome of Interstitial Cystitis:1-year Follow-up （Poster notice，General） 2014/10/13
69.	ERECTILE DYSFUNCTION RISK FACTORS IN PATIENTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA SYNDROME AND IDENTIFYING CPAP RESPONSE PREDICTORS （Poster notice，General） 2014/09/22
70.	Template-based lymphadenectomy reduced the risk of regional node recurrence in patients with renal pelvic cancer. （Poster notice，General） 2014/05/20
71.	Risk factors and management of unruptured renal artery pseudoaneurysms immediately after laparoscopic partial Nephrectomy. （Speech，General） 2014/05/19
72.	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. （Poster notice，General） 2014/05/17
73.	Erectile dysfunction risk factors in patients with severe obstructive sleep apnea syndrome and identifying CPAP response predictors. （Poster notice，General） 2014/05/06
74.	RESUL OF TRANSURETHRAL URETEROLITHOTRIPSY(TUL) AND CLINICAL CHARACTERISTICS OF ACUTE PYELONEPHRITIS FOLLWING TUL （Speech，General） 2013/10/25
75.	Efficacy of Ho:YAG laser in the treatment of ulcers in interstitial cystitis （Speech，General） 2013/09/10
76.	Advantages of transperitoneal approach over retroperitoneal approach in laparoscopic radical nephrectomy for renal cancer in patients with dialysis-dependent, end-stage renal disease （Speech，General） 2013/09/09
77.	Impact Of Preoperative C-Reactive Protein On Survival Of Patients On Chronic Hemodialysis Undergoing Nephrectomy For Renal Cell Carcinoma （Speech，General） 2013/08/31
78.	Risk Factor for Erectile Dysfunction in Patients with SAS and Predictor Identifying Responders to CPAP （Poster notice，General） 2013/06/27
79.	INCIDENCE OF ED IN MEN WITH SLEEP APNEA SYNDROME （Speech，General） 2013/06/01
80.	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease （Poster notice，General） 2013/05/20
81.	Usefulness of temporary inferior vena cava filter in preventing intraoperative pulmonary embolism for patients with renal cell carcinoma extending into inferior vena cava thrombus （Poster notice，General） 2013/05/07
82.	Better kidney functional recovery in patients with de novo CKD after partial nephrectomy compared to those with pre-existing CKD （Speech，General） 2013/05/06
83.	Enhanced CT after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm （Poster notice，General） 2013/05/06
84.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis - Multi-institutional prospective study - （Speech，General） 2013/05/06
85.	Wnt-1 signaling protein (Wisp-2/CCN5) stimulates angiogenesis and invasion in Prostate cancer （Poster notice，General） 2013/05/05
86.	Laparoscopic Radical Prostatectomy in our institute （Speech，General） 2013/04/25
87.	Therapeutic benefit from template-based lymphadenectomy in urothelial carcinoma of the renal pelvis （Speech，General） 2013/03/18
88.	Wnt-1 signaling protein (Wisp-2/CCN5) stimulates angiogenesis and invasion in Prostate cancer （Poster notice，General） 2013/02/14
89.	Analysis of factors associated with perioperative outcomes in patients with dialysis-dependent end-stage renal disease undergoing laparoscopic radical nephrectomy （Speech，Panelist at Symposium/Workshop (Other)） 2013/02/09
90.	Anatomic complexity quantitated by nephrometry score ssociated with kidney function after partial nephrectomy （Speech，General） 2013/02/08
91.	Wnt signaling protein (Wisp-2/CCN5) stimulates angiogenesis and invasion in Prostate cancer （Poster notice，General） 2013/01/31
92.	Impact of RENAL nephrometry Score on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/10/01
93.	No Impact of Mannitol on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/10/01
94.	Safty of Partial Nephrectomy for Patients on Chronic Anticoagulant Therapy （Speech，General） 2012/10/01
95.	Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to the ERA Including PRE-Cytokine,Cytokine and Targeted Therapy （Speech，General） 2012/08/18
96.	No Impact of Mannitol on Renal Function after Partial Nephrectomy in Solitary Kidneys （Speech，General） 2012/08/18
97.	Significant Negative Impact of Papillary Histological Subtype in Patients with Renal Cell Carcinoma Extending into the Inferior Vena Cava in Comparison to Clear Cell Subtype:Single-Center Experience （Speech，General） 2012/05/22
98.	Favorable Impact of Routine Screening of kidneys on the Overall Survival of Patients with Renal Cell Carcinoma Associated with End Stage Renal Disease under Chronic Dialysis Therapy （Poster notice，General） 2012/05/21
99.	Predictors for Postoperative Renal Function after Partial Nephrectomy-Including Postoperative Biomarkers （Poster notice，General） 2012/05/21
100.	Renal Cell Carcinoma(RCC) in Patients with End-stage Renal Disease: Does it really exhibit favorable prognosis compared to sporadic RCC? （Poster notice，General） 2012/05/20
101.	MRI detectability of cancer in the anterior compartment of the prostate: three-dimensional comparison with radical prostatectomy specimen （Poster notice，General） 2012/03/01
102.	Effect of WNT singnaling protein (WISP2/CCN5) stimulates angiogenesis and invasion in prostate cancer （Speech，General） 2012/02/03
103.	Wnt Signaling Protein(Wisp2/CCN5) Stimulates Angiogenesis And Invasion In Prostate Cancer （Speech，General） 2011/10/05
104.	Incidence of lymph node involvement according to pathological T stage or tumor grade in the urothelial carcinoma of the upper urinary tract （Speech，General） 2011/08/13
105.	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients-Comparison between unilateral and bilateral occurrence （Speech，General） 2011/08/13
106.	The increased utilization of partial nephrectomy for patients with renal cell carcinoma with the normal contralateral kidney-the influence of tumor size on the choice surgical procedure in this expert single center （Speech，General） 2011/05/16
107.	WNT singnaling protein (WISP2/CCN5) stimulates angiogenesis and invasion in prostate cancer （Speech，General） 2011/05/16
108.	No inpact of tumor location on the residual renal function after nephron-sparing surgery in the patients with renal tumors （Speech，General） 2010/11
109.	Renal cell carcinoma(RCC) in patients with autosomal dominant polycystic kidney diesease(ADPKD) （Speech，General） 2010/11
110.	Greater impact of lymphadenectomy according to the regional node template on the survival of patients with urothelial carcinoma of the upper urinary tract-a comparison between the template and the total number of lymph nodes removed （Speech，General） 2010/05
111.	No impact of tumor location on the residual renal funtion after nephron-sparing surgery in the patients with renal tumors （Speech，General） 2010/05
Display 5 items
Display all(111)

■ Education

1994/04～1998/03

〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed,